Lipid-based Nanosized Delivery Systems for Fluoroquinolones: A Review

被引:13
作者
Furneri, Pio Maria [1 ]
Fuochi, Virginia [1 ]
Pignatello, Rosario [2 ]
机构
[1] Univ Catania, BIOMETEC, Dept Biomed & Biotechnol Sci, Catania, Italy
[2] Univ Catania, Dept Drug Sci, Catania, Italy
关键词
Lipid nanocarriers; SLN; NLC; quinolone; norfloxacin; ciprofloxacin; ofloxacin; enrofloxacin; gatifloxacin; levofloxacin; IN-VITRO ACTIVITY; OFLOXACIN-LOADED LIPOSOMES; CONTROLLED DRUG-DELIVERY; AMPHIPHILIC ION-PAIRS; NANOPARTICLES SLN; ANTIBACTERIAL ACTIVITY; CARRIERS NLC; ANTIMICROBIAL ACTIVITY; MICROBIOLOGICAL ASSAY; INVITRO ACTIVITY;
D O I
10.2174/1381612823666171122110103
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The class of fluoroquinolone antibiotics, due to its core chemical modifications, is considered as wide-spectrum antibacterial drugs with useful pharmacokinetic and pharmacodynamic properties. However, because of their poor solubility in water, they are used as salts (lactates or hydrochlorides). Fluoroquinolones, bacterial membranes and eukaryotic cell membranes interactions are well known and their permeation properties are well investigated. In fact, they are concentrated inside the cells and intracellular compartments. Nanotechnology in Drug Delivery has developed many supra-molecular structures that have been used to improve both pharmacokinetic and pharmacodynamic properties. The main results of the published papers showed reduction of toxicity, higher intracellular concentrations (both bacteria and eukaryotic), enhancement of antimicrobial activity, prolonged drug release, decreased mortality in animal model studies, improved water solubility and improved in vitro efficacy against intracellular pathogens. Methods: a literature search was performed in the NCBI-PUBMED database, with no time range, using the keywords "solid lipid nanoparticles" and 'quinolones' or the name of single antibiotics. Results: the most important aspects of lipid-based nanocarrier technology used for fluoroquinolones have been highlighted, with a focus on the latest formulation developments that have led to significant improvements of pharmacokinetics and pharmacodynamics. Both technological and microbiological aspects of published papers have been discussed. Conclusion: the potentiality of using lipid nanoparticles to improve the efficacy and potency of quinolone antibiotics has been supported by recent scientific publications, although some criticism appeared due to the microbiological investigative methods used and because of lack of systematic evaluation about the influence of technological approaches to the in vitro and in vivo drug activity.
引用
收藏
页码:6696 / 6704
页数:9
相关论文
共 135 条
[1]   Nanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections [J].
Abed, Nadia ;
Couvreur, Patrick .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 43 (06) :485-496
[2]   Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin [J].
Abul Kalam, Mohd. ;
Sultana, Yasmin ;
Ali, Asgar ;
Aqil, Mohd. ;
Mishra, Anil K. ;
Aljuffali, Ibrahim A. ;
Alshamsan, Aws .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2013, 101 (06) :1813-1827
[3]   Part II: Enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops [J].
Abul Kalam, Mohd. ;
Sultana, Yasmin ;
Ali, Asgar ;
Aqil, Mohd. ;
Mishra, Anil K. ;
Chuttani, Krishna ;
Aljuffali, Ibrahim A. ;
Alshamsan, Aws .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2013, 101 (06) :1828-1836
[4]   Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases [J].
Andrade, Fernando ;
Rafael, Diana ;
Videira, Mafalda ;
Ferreira, Domingos ;
Sosnik, Alejandro ;
Sarmento, Bruno .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (13-14) :1816-1827
[5]   The quinolones: Past, present, and future [J].
Andriole, VT .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S113-S119
[6]  
[Anonymous], 2017, CLSI Suppl, pM100
[7]  
[Anonymous], 2016, EUROPEAN PHARMACO S9, P3
[8]  
[Anonymous], 2015, Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria, V3rd
[9]   The fluoroquinolone antibacterials: past, present and future perspectives [J].
Appelbaum, PC ;
Hunter, PA .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (01) :5-15
[10]   Targeted delivery of nanoparticles for the treatment of lung diseases [J].
Azarmi, Shirzad ;
Roa, Wilson H. ;
Loebenberg, Raimar .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (08) :863-875